CTRI/2022/09/045464招募中4 期
CONTROL – A Phase IV, open-label, multi-centric, non-comparative study to assess the efficacy and tolerability of fixed dose combination (FDC) of metoprolol and telmisartan (Metosartan) in patients with essential hypertension.
Sun Pharma Laboratories Limited SP0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female patients aged between 18 and 65 years (both inclusive) willing to provide written informed consent.
- •Patients diagnosed with essential hypertension with co-existing stable ischemic heart disease [no change in severity of symptoms or nitrate
- •consumption in previous 3 months and defined as either stable symptoms (angina or dyspnea), which are thought to be related to chronic arterial disease (CAD), or asymptomatic patients with prior-diagnosed CAD].
- •Patients with uncontrolled essential hypertension [having seated diastolic BP (SeDBP) 90 to 110 mmHg and/or seated systolic BP (SeSBP) 140 to 200 mmHg based on in-clinic blood pressure AND 24-hr average SBP = 130 and/or DBP = 80 mmHg based on ABPM], heart rate of >70 beats/minute and who is on stable dose of antihypertensive monotherapy for at least 4 weeks.
- •Patients recommended FDC of Metoprolol succinate extended release + Telmisartan as part of physician’s clinical decision, in line with the prescribing information (PI) of Metosartan.
- •Female subjects of childbearing potential must have a negative urine pregnancy test prior to study entry and must be willing to use acceptable method of contraception (female of childbearing potential is defined as one who has not been postmenopausal for at least one year, or has not been surgically sterilized, or has not had a hysterectomy at least three months prior to the start of this study. Acceptable method of contraception includes (e.g., barrier method with spermicide). The calendar method or usage of intra-uterine device (IUD) will not be considered as an acceptable method. The patient must be willing to practice recommended and acceptable method of contraception to prevent pregnancy from the time of study entry till 2 weeks post the last dose of study medication.
排除标准
- •Presence of any clinically relevant known comorbid conditions like hepatic impairment, chronic renal failure, thromboembolic disorders, cerebrovascular diseases, uncontrolled diabetes, uncontrolled thyroid disorder etc.
- •Any known cardiac disease/disorder like severe bradycardia, heart block greater than first degree or significant first-degree block, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome without pacemaker etc. in which either Metoprolol or Telmisartan (individually or in combination) is contraindicated.
- •Presence or history of secondary or malignant hypertension.
- •Female subjects who are pregnant or lactating or are likely to become pregnant
- •Patients receiving other beta blocker therapy (other than Metoprolol) in the last 4 weeks of treatment period prior to entering the study
- •Any relevant clinical condition which, in the opinion of the investigator, could interfere with the outcome of the study.
- •Patients expected to be non-compliant to the recommended instructions of the treating physician.
- •Concomitant or prior (within 60 days of screening) use of any of the following medications: calcium channel blockers, digitalis glycosides, MAO inhibitors, fluoxetine, paroxetine, propafenone, quinidine, ACE inhibitors, clonidine, aliskiren.
- •Patients who have participated in any study of an investigational product within last months.
- •Subjects with known intolerance, hypersensitivity or any other contraindication to any of Metoprolol or Telmisartan.
研究者
相似试验
进行中（未招募）
不适用
A Study to Evaluate long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine (free of protein-derived stabilizer) In children and adolescentsProphylaxis: Tick-borne-encephalitisEUCTR2014-005105-20-Outside-EU/EEAovartis Vaccines and Diagnostics232
进行中（未招募）
不适用
This is an extension study, V59P20E1 of V59P20,in which the sponsor was planning to assess 5-year antibody persistence in subjects who received one or two doses of MenACWY conjugate vaccine at 2 to 10 years of age, and to evaluate response to a booster dose administered 5 years after primary vaccination.Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose.EUCTR2014-004446-95-Outside-EU/EEAovartis Vaccines and Diagnostics500
进行中（未招募）
不适用
A Phase IV, Multi-Center, Controlled, Open-label Study to Evaluate the Safety,Tolerability and Immunogenicity of Chiron Meningococcal C Conjugate VaccineMenjugate® when Given as First, Third or Fourth Immunization to Children 32 to 40Months of Age - N/AEUCTR2004-005150-31-DEChiron Behring GmbH & Co. KG
已完成
4 期
A Phase IV Clinical Study to Evaluate the Safety and Efficacy of ComVac5 (DTwP-Hep-B-Hib, Liquid Pentavalent vaccine of Bharat Biotech)CTRI/2010/091/001128Bharat Biotech International Limited300
进行中（未招募）
不适用
Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi®, Onicit®, Paloxi®) in the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Non-Hodgkin’s Lymphomas Undergoing Repeated Cycles of Moderately Emetogenic ChemotherapyPrevention of moderately emetogenic CINV in up to four repeated and consecutive single-day MEC cycles administered to patients with Non-Hodgkin’s Lymphomas.MedDRA version: 13.1Level: PTClassification code 10054133Term: Prophylaxis of nausea and vomitingSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2008-007827-14-DEHelsinn Healthcare SA200